Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	29.20B
Revenue (ttm)	11.58B
Net Income (ttm)	570.05M
Shares Out	231.00M
EPS (ttm)	2.47
PE Ratio	51.22
Forward PE	n/a
Dividend	2.00 (1.55%)
Ex-Dividend Date	Oct 28, 2024

Volume	393,204
Average Volume	191,543
Open	130.70
Previous Close	130.70
Day's Range	127.30 - 130.70
52-Week Range	104.80 - 252.50
Beta	-0.37
RSI	48.04
Earnings Date	Apr 30, 2025

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,162
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2024, Beacon Pharmaceuticals's revenue was 10.70 billion, an increase of 25.76% compared to the previous year's 8.51 billion. Earnings were 521.01 million, an increase of 2.19%.